Armata Obtains FDA Agreement for Pediatric Study of AP-SA02

Armata Pharmaceuticals received FDA agreement on the Initial Pediatric Study Plan (iPSP) for AP-SA02 to treat resistant staph infections in children. This regulatory milestone advances the company toward a Biologics License Application for pediatric patients.